-
A phase I trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenously administered low-anticoagulant heparin (M6229) in critically ill sepsis patients
van Mourik, N., van Amstel, R. B. E., Slim, M. A., van Vught, L. A., van der Poll, T., Huckriede, J., de Vries, F., de Kimpe, S. J., Crabbé, R., van Leeuwen, S. J. M., Ekhart, P. F., Reutelingsperger, C. P. M., Nicolaes, G. A. F., Vlaar, A. P. J. & Müller, M. C. A., 1 Dec 2025, In: Intensive Care Medicine Experimental. 13, 1, 84.Research output: Contribution to journal › Article › Academic › peer-review
-
Immunobiological effects of tocilizumab across respiratory subphenotypes in COVID-19 ARDS
Rademaker, E., Filippini, D. F. L., Haitsma Mulier, J. L. G., Slim, M. A., van Amstel, R. B. E., Bhavani, S. V., Juffermans, N. P., de Grooth, H.-J. S., Derde, L. P. G., Cremer, O. L. & Amsterdam U. M. C. COVID-19 Biobank Study Group, 1 Dec 2025, In: Intensive Care Medicine Experimental. 13, 1, 70.Research output: Contribution to journal › Article › Academic › peer-review
-
Towards novel BIOmarkers to diagnose SEPsis (BIOSEP) in the emergency room: a protocol for a multicentre, prospective cohort study
Reijnders, E., Turgman, O., Joosten, S. C. M., Schinkel, M., Slim, M. A., Douma, R. A., Moeniralam, H. S., Peters-Sengers, H., van der Poll, T. & Wiersinga, W. J., 1 Aug 2025, In: BMJ open. 15, 7, e103138.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
